Outcomes of Focal Ablation for Prostate Cancer

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT05478694
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Study Details

This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

Key Dates

Start date
Feb 1, 2023
Status verified
Apr 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
225 participants (estimated)

Arms

  • Arm: Ablative Therapy Group
    Enrolled subjects will undergo the ablative therapy as part of their standard of care treatment

Primary Outcome Measure

Oncologic outcomes as assessed by the rate of negative in-field biopsy at 12 months (primary setting) [ Time Frame: 12 months post treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UTSWDallasTexas75390
Sonobia Garrett

Find similar trials in Dallas, TX

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
UTSW· Dallas, TX

Related Studies